Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl + ondansetron is a combination of two pharmaceutical agents used together, typically in perioperative or postoperative settings. Fentanyl is a potent synthetic opioid analgesic that acts primarily as an agonist at the mu-opioid receptor, providing strong pain relief and sedation. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that prevents nausea and vomiting by blocking serotonin action in both the central nervous system and gastrointestinal tract. This combination may be used to manage pain (via fentanyl) while reducing the risk of opioid-induced or postoperative nausea and vomiting (via ondansetron). There are no widely recognized fixed-dose combination products containing both drugs; they are generally administered separately but concurrently for their complementary effects[2][1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + ondansetron.